ARCHIVES

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

This article is from The Cancer Letter archive.

Vol. 35 No. 5 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

DCPC Advisors Okay New Program Project Grants In Prevention

January 27, 1995

Cornel Student Withdraws In Wake Of Discrepancies Found In Study

September 18, 1981

NCI Advisory Group Meetings for July

June 27, 1975

In Brief: Antman, Chabner Vie For ASCO President-Elect; Irwin Krakoff Is 1993 Karnofsky Lecturer

January 8, 1993

In Brief: Peter Jones Is Interim director of USC’s Norris; NIAMS Funds Skin Disease Corse At Yale, Texas

January 1, 1993

NCI Spent $381.2 Million On PR From 2006 to 2012, Vastly Outspending Other NIH, FDA Units

March 1, 2013